CASI Pharmaceuticals, Inc. CASIF

CASIF Company Overview

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of oncology and immunology therapeutics, with a primary strategic emphasis on the China market. The company operates in the biotechnology and pharmaceutical industries, targeting cancers and immune-related diseases with high unmet medical need. CASI’s business model centers on in-licensing, developing, and commercializing late-stage drug candidates, particularly those that can leverage regulatory and market opportunities in Greater China.

The company’s primary revenue drivers are product sales and licensing-related income from approved or late-stage therapeutic assets, as well as milestone and collaboration payments where applicable. CASI positions itself as a bridge between Western-developed pharmaceutical assets and the Chinese healthcare market, aiming to accelerate time-to-market through localized clinical development and regulatory execution. Founded in 1991 (originally as EntreMed, Inc.), the company underwent a strategic transformation beginning in the mid-2010s, rebranding as CASI Pharmaceuticals and refocusing its operations on oncology and China-centric commercialization.